20 Feb 2004
Sun Microsystems has unveiled a radio frequency identification (RFID) product designed to combat the growing problem of drug counterfeiting.
Pharmaceutical Anti-Counterfeit RFID, designed in partnership with SupplyScape Corporation, will be offered to companies in the pharmaceutical supply chain to combat counterfeiting.
Further reading
The package is based on Sun Java Enterprise System Software and Sun's RFID Electronic Product Code-compliant infrastructure software.
It also uses SupplyScape's Electronic Pedigree application and runs on Linux or Sun Solaris x86-based servers.
The launch was timed to coincide with a US Federal Drug Administration (FDA) Counterfeit Drug Task Force report, Combating Counterfeit Drugs, released yesterday.
"RFID technology will make the copying of medications either extremely difficult or unprofitable," the report stated.
The FDA said that these technologies could create a record of all transactions involving pharmaceutical products, thus providing an electronic pedigree from the manufacturer to the point of dispensing.
Liz From, life science industry manager at Sun, said in a statement: "The same technology offers short-term ROI by taking cost out of pharmaceutical supply chain operations."
Latest stories from Web
Related articles
Related jobs
Poll
What is the most important IT priority for your company this year?
Sneak peek at the forthcoming glass-based machine
Connect with V3.co.uk
This paper focuses on a series of best practices and techniques for development teams looking to improve their software development processes
Why good data management at all levels is essential in the modern business (video, 6mins)
C++ GUI Developer - Financial Services - London Tech...
This is an opportunity for a bright and talented Java...
C# Application Developer Location : Nottingham...
Experienced Web Developer Wanted for Financial Sector...
Keep up to date with the latest products, services and technologies from the world's leading IT companies. IThound.com brings you over 2,000 white papers, case studies and analyst reports.
Do you agree?